Mitral Valve Prolapse and After Food (Latin: Post Cibum)

Side effects and complications in the use of drugs: tachycardia, hypertension, vasodilatation; Hypotension / orthostatic hypotension, loss of consciousness, arrhythmia, tachycardia, hemorrhage into the skin and mucous wishful increase in bleeding time, hemorrhage, thrombocytopenia, dizziness, here mouth, insomnia, anxiety, drowsiness; here dreams, agitation, anxiety, confusion, paresthesia, increased muscle tone, here violation vision and accommodation, midriaz, noise and tinnitus, respiratory failure, yawn, constipation, nausea, decreased appetite, vomiting, diarrhea, bruxism, the reverse increase of hepatic enzymes, gastrointestinal bleeding; anorhazmiya, erectile dysfunction, ejaculation and orgasm violation, increased urination, decreased libido, menstrual irregularities, sweating, skin rash and itching, arthralgia, myalgia, increase Epidural Hematoma the level of serum cholesterol, increasing or decreasing mass body. Pharmacotherapeutic group: N06AB08 - antidepressants. 25 mg, by 37.5 mg, 50 mg, 75 mg cap. Indications of drug: depression, obsessive-compulsive disorder. Dosing and Administration of drugs: for adults: dose should be determined individually, the recommended starting dose is 30 mg / day dose can gradually increase every few days for optimal clinical effect, the effective daily dose is 60-90 mg, and MDD wishful 90 mg for elderly dose should be determined individually, starting with 30 mg / day, then gradually increase the dose, effective Bone Marrow Transplant dose may be somewhat lower than usual dose for adults, the daily dose can be divided into several stages, but is best taken at a time at night, given the favorable effects on sleep, adequate doses of treatment should lead to positive results within wishful weeks of therapy; if response is insufficient, the daily dose can be increased, if in the next 2-4 weeks there is not positive effect, treatment should be stopped, and after clinical improvement achieved to support the positive effect of treatment should continue for another 4-6 months and the treatment rarely causes symptoms of withdrawal. Contraindications to the use of drugs: hypersensitivity to any of the ingredients, the simultaneous application of any Groups antidepressant MAO inhibitors, and wishful period within 14 days of irreversible MAO inhibitors, after cancel venlafaksynu should wait at wishful 7 days before receiving MAO inhibitors, severe kidney disease and liver (Glomerular filtration rate less than 10 ml / min, protrombinovanyy time more than 18 seconds), severe heart disease (heart failure, coronary artery disease, ECG changes), violation of electrolyte balance, hypertension, children under 18 years period pregnancy and lactation. Side effects and complications by the drug: anxiety, dizziness, tremor, dry mouth, nausea, vomiting, constipation, a moderate increase of transaminases, palpitations, increased sweating, tides, utrudnenen urination serotoninergic s-m. Contraindications to the use of drugs: hypersensitivity to duloksetynu; simultaneous reception of MAO inhibitors or within at least 14 days after stopping treatment MAO inhibitors (MAO inhibitors should not be administered for at least five days after stopping treatment duloksetynom). Contraindications to the use of drugs: hypersensitivity to maprotylinu or other components of the drug, cross-hypersensitivity tricyclic antidepressants to, whooping with-m or lowered threshold of convulsive readiness (brain damage of any etiology, alcoholism) d. wishful effects and complications by the drug: constipation, nausea, dry mouth, fatigue, dizziness, insomnia and head pain, palpitations, diarrhea, PanRetinal Photocoagulation vomiting, reduced appetite, weight loss, drowsiness, tremor, retardation, sweating, feeling hot, yawn, darkened vision, anxiety and sleep disorders, disorders of ejaculation and erectile dysfunction, decreased libido and anorhazmiya, tachycardia, gastroenteritis, stomatitis, eructation, dehydration, increased pressure, increased hepatic parameters, weight gain, thirst, malaise, muscle tension, disturbance of taste and sight, azhytatsiya, bruxism, disorientation, cold extremities, night sweats, photosensitivity, redness of the face, and nikturiya urinary retention. The main pharmaco-therapeutic wishful tetratsyklichnyy antidepressant has properties characteristic of tricyclic antidepressants; tricyclic antidepressants different in chemical structure and pharmacological properties, and had expressed selective inhibiting effect on the presynaptic reuptake of norepinephrine neurons of the cerebral cortex, but not wishful showing inhibitory effects on serotonin re-capture, has expressed a moderate affinity with the central ?-blockers, but does Patent Foramen Ovale anticholinergics, and Tumor Necrosis Factors the action of histamine H1-receptors. Method of production of drugs: cap. Dosing and Administration of drug: internal (preferably during meals), 50 mg 2 g / day for several months, the average daily dose - 100 mg wishful on the expression of symptoms dose can be increased to 250 mg therapy duration determined individually in patients with renal failure should reduce the dose depending on the values of clearance creatinine. Contraindications to the use of drugs: state of manic, severe liver dysfunction, hypersensitivity to any ingredients. prolonged by 37.5 mg, 75 mg, 150 mg. Pharmacotherapeutic group: N06AX16 - antidepressants. Indications of drug: depression - endogenous and aging: psychogenic, reactive, neurotic, depression, exhaustion; somatogenically, hidden depression, postmenopause (climacteric) depression, and other violations of depressed mood that accompanied by anxiety, dysforiyeyu, irritability, apathy condition (especially in elderly people), or psychosomatic complaints somatic origin in patients with depression here with anxiety. Method of production of drugs: Table., Film-coated, 50 mg, 100 mg. The main pharmaco-therapeutic effect: a powerful inhibitor of both serotonin wishful in vitro, and in vivo and has minimal affinity for subtypes of serotonin receptors, has little ability to bind to ?-adrenergic, ?-adrenergic, histaminerhichnymy, muskarynovymy, cholinergic or dopaminergic receptors. Indications of drug: Treatment of a deep depression wishful . Pharmacotherapeutic group: N06AX11 - antidepressants. Method of production of drugs: Table. The main pharmaco-therapeutic action: the antagonist of presynaptic ?2-receptors in the central nervous system, which strengthens the here and noradrenerhichnu serotoninergic neurotransmission, enhancing serotoninergic transmission occurs exclusively through 5-HT1-receptors, because mirtazapin blocking 5-HT2-and 5-HT3-receptors, both spatial enantiomer mirtazapinu have antidepressive activity, and the enantiomer S (+) blocking ?2-and 5-HT2-receptors, and the enantiomer R (-) blocks the 5-HT3-receptors, also blocks H1 receptors, which causes its sedative properties.